A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02498613 |
|
Recruitment Status :
Active, not recruiting
First Posted : July 15, 2015
Last Update Posted : April 12, 2024
|
Sponsor:
National Cancer Institute (NCI)
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
National Cancer Institute (NCI)
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Actual Primary Completion Date : | June 22, 2022 |
| Estimated Study Completion Date : | April 10, 2025 |
| Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
|---|---|---|
| 1 |
April 24, 2024 |